搜尋結果
4 天前 · By Michael Erman. (Reuters) - Novavax will only be able to offer a COVID-19 vaccine in the United States this autumn if regulators accept the shot it has started manufacturing that targets a ...
2024年5月10日 · (Reuters) -Novavax on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi for its COVID-19 vaccine in exchange for a stake that valued the U.S. biotech firm at ...
2024年5月20日 · Under a deal signed on May 10, the French drugmaker will take a 4.9% stake in Novavax for $70 million at a lofty valuation. It includes an upfront cash payment of $500 million and future payments...
6 天前 · Experts weigh in. When COVID-19 vaccines entered the commercial market last fall, the federal government introduced a program to make shots accessible to people with limited coverage or no ...
- 35 秒
- Eduardo Cuevas, USA TODAY
4 天前 · Novavax, which makes a more traditional protein-based vaccine that takes longer to manufacture, has begun producing a shot targeting JN.1 consistent with recommendations from European regulators.
2024年5月6日 · Anyone age 12 and older is eligible for the updated Novavax vaccine, which uses a more traditional protein-based approach. But few Americans have taken advantage.
2024年5月13日 · The new "FLiRT" COVID-19 variants, including KP.2, are spreading in the United States. Will there be a summer surge? Experts discuss KP.2 transmission, symptoms, and vaccines.
